ITGAM and neoplasm: As shown in Fig 4, β-blocker treatment significantly abrogated the CD11b+F4/80+ macrophages population in the primary tumor tissue (PS vs. BS: 6.71 ± 0.57% of live cells vs. 10.33 ± 1.01%, P = 0.0353; IS vs.BS: 6.60 ± 0.68% of live cells vs. 10.33 ± 1.01%, P = 0.0374).